Key advances Clinical trials of the IL-23p19 antibodies guselkumab and risankizumab have demonstrated that they are safe and effective for induction and maintenance of remission in moderately to severely active Crohn’s disease^{ 1 – 3 }. A phase III trial of the novel Janus kinase inhibitor upadacitinib demonstrated its efficacy in patients with moderately to severely active ulcerative colitis who either had or had not previously received biologic therapy^{ 5 }. A phase III trial of the oral integrin α4 inhibitor carotegrast methyl (AJM300) demonstrated its efficacy as an induction therapy in mildly to moderately active ulcerative colitis; the drug is now approved for clinical use in Japan^{ 6 }. Head-to-head comparison of adalimumab and ustekinumab in moderately to severely active Crohn’s disease in the SEAVUE study showed that their efficacy is similar^{ 8 }.
【저자키워드】 drug therapy, Inflammatory bowel disease, Crohn's disease,